Podcast

Speaking of Urology: What patients undergoing HIFU should expect postoperatively

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, explains what he tells patients undergoing HIFU to expect postoperatively.

Catch up on "Speaking of Urology":

A HIFU expert discusses his treatment criteria

Dr. Angela Smith discusses Jelmyto for low-grade UTUC

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC
February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke
The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Prostate cancer cells, 3D illustration| © Dr_Microbe - stock.adobe.com
February 14th 2025

Real-world studies underline safety, efficacy of radium-223 in mCRPC

Benjamin P. Saylor
A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Blur image of hospital | Image Credit: © jakkapan - stock.adobe.com
February 14th 2025

Radium-223 re-treatment is safe in patients with mCRPC

Benjamin P. Saylor
The median number of re-injections was 6 (range, 1-12).
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor
"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.
© 2025 MJH Life Sciences

All rights reserved.